3D-Pharmacophore Models for Selective A2A and A2B Adenosine Receptor Antagonists

Three-dimensional pharmacophore models were generated for A2A and A2B adenosine receptors (ARs) based on highly selective A2A and A2B antagonists using the Catalyst program. The best pharmacophore model for selective A2A antagonists (Hypo-A2A) was obtained through a careful validation process. Four features contained in Hypo-A2A (one ring aromatic feature (R), one positively ionizable feature (P), one hydrogen bond acceptor lipid feature (L), and one hydrophobic feature (H)) seem to be essential for antagonists in terms of binding activity and A2A AR selectivity. The best pharmacophore model for selective A2B antagonists (Hypo-A2B) was elaborated by modifying the Catalyst common features (HipHop) hypotheses generated from the selective A2B antagonists training set. Hypo-A2B also consists of four features: one ring aromatic feature (R), one hydrophobic aliphatic feature (Z), and two hydrogen bond acceptor lipid features (L). All features play an important role in A2B AR binding affinity and are essential for A2B selectivity. Both A2A and A2B pharmacophore models have been validated toward a wide set of test molecules containing structurally diverse selective antagonists of all AR subtypes. They are capable of identifying correspondingly high potent antagonists and differentiating antagonists between subtypes. The results of our study will act as a valuable tool for retrieving structurally diverse compounds with desired biological activities and designing novel selective adenosine receptor ligands.

[1]  S. Moro,et al.  Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation. , 2003, Journal of medicinal chemistry.

[2]  E. Israel,et al.  Treatment of asthma with drugs modifying the leukotriene pathway. , 1999, The New England journal of medicine.

[3]  K. Jacobson,et al.  Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. , 2000, Journal of medicinal chemistry.

[4]  C. Müller,et al.  Development of spin-labeled probes for adenosine receptors. , 2005, Journal of medicinal chemistry.

[5]  H. V. van Vlijmen,et al.  Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists. , 2004, Journal of medicinal chemistry.

[6]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[7]  J. Lipsky,et al.  Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice. , 1998, Mayo Clinic proceedings.

[8]  G. Burnstock,et al.  Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells , 1996, Trends in Neurosciences.

[9]  Giovanni Piersanti,et al.  2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. , 2005, Journal of medicinal chemistry.

[10]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[11]  Irini A. Doytchinova,et al.  CoMFA Study on Adenosine A2A Receptor Agonists , 2001 .

[12]  C. Müller,et al.  1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.

[13]  J. Downey,et al.  Adenosine-induced vasodilation: receptor characterization in pulmonary circulation. , 1995, The American journal of physiology.

[14]  Y. Kurogi,et al.  1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands. , 2002, Journal of medicinal chemistry.

[15]  S. Hourani,et al.  Role of cyclic nucleotides in vasodilations of the rat thoracic aorta induced by adenosine analogues , 2001, British journal of pharmacology.

[16]  G. Spalluto,et al.  7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. , 2002, Journal of medicinal chemistry.

[17]  B. Neustadt,et al.  The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[18]  J. Grider,et al.  Adenosine A1 and A2b receptors coupled to distinct interactive signaling pathways in intestinal muscle cells. , 1995, The Journal of pharmacology and experimental therapeutics.

[19]  K. Varani,et al.  Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  A. Ivanov,et al.  Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists. , 2005, Journal of Medicinal Chemistry.

[21]  R. Howell,et al.  Mechanism for the emetic side effect of xanthine bronchodilators. , 1990, Life sciences.

[22]  S. Moro,et al.  Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen. , 2000, Journal of medicinal chemistry.

[23]  I. Biaggioni,et al.  Adenosine-Activated Mast Cells Induce IgE Synthesis by B Lymphocytes: An A2B-Mediated Process Involving Th2 Cytokines IL-4 and IL-13 with Implications for Asthma12 , 2004, The Journal of Immunology.

[24]  E. Jackson,et al.  Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. , 1998, Hypertension.

[25]  K. Klotz,et al.  Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. , 2000, Journal of medicinal chemistry.

[26]  Jan Balzarini,et al.  Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. , 2005, Journal of medicinal chemistry.

[27]  T. Engber,et al.  Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists. , 2004, Bioorganic & medicinal chemistry letters.

[28]  K. Varani,et al.  Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. , 2004, Journal of medicinal chemistry.

[29]  K. Jacobson,et al.  1,3‐dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors , 1999, Drug development research.

[30]  K. Jacobson,et al.  Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. , 2002, Journal of medicinal chemistry.

[31]  E. Ongini,et al.  Adenosine A2A Receptors and Neuroprotection , 1997, Annals of the New York Academy of Sciences.

[32]  K. Jacobson,et al.  P1 and P2 Purine and Pyrimidine Receptor Ligands , 2001 .

[33]  I. Feoktistov Adenosine A 2 B Receptors , 1998 .

[34]  K. Jacobson,et al.  Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor. , 1994, European journal of pharmacology.

[35]  H. Kase,et al.  Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. , 1993, Journal of medicinal chemistry.

[36]  D. Zeng,et al.  The discovery of a selective, high affinity A(2B) adenosine receptor antagonist for the potential treatment of asthma. , 2005, Bioorganic & medicinal chemistry letters.

[37]  Thea Mulder-Krieger,et al.  2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. , 2004, Journal of medicinal chemistry.

[38]  K. Klotz,et al.  8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists. , 1998, Bioorganic & medicinal chemistry.

[39]  P. Jenner,et al.  Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. , 1997, Trends in pharmacological sciences.

[40]  G. Chrousos,et al.  Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical implications. , 2000, Annals of the New York Academy of Sciences.

[41]  K. Varani,et al.  New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. , 2005, Journal of medicinal chemistry.

[42]  K. Jacobson,et al.  Acyl‐hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptors , 1999 .

[43]  K. Varani,et al.  New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists. , 2005, Journal of medicinal chemistry.